Onpattro™ (Patisiran)

Policy Number: 2019D0072E  Effective Date: August 1, 2019

Table of Contents

<table>
<thead>
<tr>
<th>Coverage Rationale</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coverage Rationale</td>
<td>1</td>
</tr>
<tr>
<td>Applicable Codes</td>
<td>2</td>
</tr>
<tr>
<td>Background</td>
<td>2</td>
</tr>
<tr>
<td>Benefit Considerations</td>
<td>2</td>
</tr>
<tr>
<td>Clinical Evidence</td>
<td>2</td>
</tr>
<tr>
<td>U.S. Food and Drug Administration</td>
<td>3</td>
</tr>
<tr>
<td>Centers for Medicare and Medicaid Services</td>
<td>3</td>
</tr>
<tr>
<td>References</td>
<td>3</td>
</tr>
<tr>
<td>Policy History/Revision Information</td>
<td>4</td>
</tr>
<tr>
<td>Instructions for Use</td>
<td>4</td>
</tr>
</tbody>
</table>

Coverage Rationale

Onpattro (patisiran) is proven for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.

Onpattro (patisiran) is medically necessary for the treatment of the polyneuropathy of hATTR amyloidosis in patients who meet ALL of the following criteria:

- For initial therapy, all of the following:
  - Both of the following:
    - Diagnosis of hATTR amyloidosis with polyneuropathy
    - Documentation that the patient has a pathogenic TTR mutation (e.g., V30M)
    - Prescribed by or in consultation with a neurologist; and
  - Documentation of one of the following:
    - Patient has a baseline polyneuropathy disability (PND) score ≤ IIIb
    - Patient has a baseline FAP Stage 1 or 2
    - Patient has not had a liver transplant; and
  - Presence of clinical signs and symptoms of the disease (e.g., peripheral sensorimotor polyneuropathy, autonomic neuropathy, motor disability, etc.); and
  - Patient is not receiving Onpattro in combination with either of the following:
    - Oligonucleotide agents [e.g., Tegsedi (inotersen)]
    - Vyndaqel (tafamidis meglumine) or Vyndamax (tafamidis)
    - Patisiran dosing is in accordance with the US Food and Drug Administration prescribing information (0.3 mg/kg up to a maximum of 30mg, every 3 weeks); and
  - Initial authorization is for no more than 12 months.

- For continuation therapy, all of the following:
  - Patient has previously received treatment with Onpattro; and
  - Prescribed by or in consultation with a neurologist; and
  - Documentation of one of the following:
    - Patient continues to have a polyneuropathy disability (PND) score ≤ IIIb
    - Patient continues to have a FAP Stage 1 or 2
    - Documentation that the patient has experienced a positive clinical response to Onpattro (e.g., improved neurologic impairment, motor function, quality of life, slowing of disease progression, etc.); and

See Related Commercial Policy

- Provider Administered Drugs – Site of Care
- Onpattro™ (Patisiran)
Patient is not receiving Onpattro in combination with either of the following:

- Oligonucleotide agents [e.g., Tegsedi (inotersen)]
- Vyndaqel (tafamidis meglumine) or Vyndamax (tafamidis)

and

- Patisiran dosing is in accordance with the US Food and Drug Administration prescribing information (0.3 mg/kg up to a maximum of 30mg, every 3 weeks); and
- Authorization is for no more than 12 months.

**Onpattro (patisiran) is unproven and not medically necessary for the treatment of:**

- Sensorimotor or autonomic neuropathy not related to hATTR amyloidosis
- Primary or leptomeningeal amyloidosis

### APPLICABLE CODES

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Coverage Determination Guidelines may apply.

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C9036</td>
<td>Injection, patisiran, 0.1 mg</td>
</tr>
<tr>
<td>J3490</td>
<td>Unclassified drugs</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ICD-10 Diagnosis Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>E85.1</td>
<td>Neuropathic heredofamilial amyloidosis</td>
</tr>
</tbody>
</table>

### BACKGROUND

Hereditary ATTR (hATTR) amyloidosis, formerly known as familial amyloid polyneuropathy, is a progressive, disabling and life-threatening polyneuropathy affecting the peripheral and autonomic nervous system. This disease is an autosomal transmission disorder which is usually due to a point mutation of the transthyretin (TTR) gene. The disease is caused by misfolded transthyretin (TTR) protein that accumulates as amyloid fibrils in multiple organs, including the nerves, heart, and gastrointestinal tract.

Onpattro (patisiran) is a double-stranded small interfering RNA (siRNA) that targets a sequence of mRNA conserved across wild-type and all TTR variants and can thereby degrade and reduce serum levels and protein deposits in tissues of both wild-type and mutated protein. It is formulated as lipid nanoparticles which direct it to the liver, the primary source of circulating TTR. Patisiran therapy is associated with observed lowering of TTR levels in both wild-type and mutant (V30M) forms of TTR.

A genetic testing service is available in the United States and Canada and a genetic counseling service is available in the United States. Medical professionals and patients may access information on the Alnylam Pharmaceuticals website.

### BENEFIT CONSIDERATIONS

Some Certificates of Coverage allow for coverage of experimental/investigational/unproven treatments for life-threatening illnesses when certain conditions are met. The member specific benefit plan document must be consulted to make coverage decisions for this service. Some states mandate benefit coverage for off-label use of medications for some diagnoses or under some circumstances when certain conditions are met. Where such mandates apply, they supersede language in the benefit document or in the medical or drug policy. Benefit coverage for an otherwise unproven service for the treatment of serious rare diseases may occur when certain conditions are met. See the Policy and Procedure addressing the treatment of serious rare diseases.

### CLINICAL EVIDENCE

A randomized, double-blind, placebo-controlled, phase III, global study (APOLLO) evaluated the efficacy and safety of patisiran in patients with hATTR amyloidosis with polyneuropathy. Adult patients 18 to 85 years of age were eligible for the study if the investigatory estimated survival to be ≥ 2 years, Neuropathy Impairment Score (NIS) of 5 to 130, and polyneuropathy disability score ≤ IIIb. Patients were randomized 2:1 (N =148:77) to receive either intravenous (IV) patisiran 0.3 mg/kg or placebo every 3 weeks. The primary endpoint was to determine the efficacy of patisiran at
18 months based on the difference in the change in modified NIS+7 (a composite measure of motor strength, sensation, reflexes, nerve conduction, and autonomic function) between the patisiran and placebo groups. Secondary endpoints evaluated the effect of patisiran on Norfolk-Diabetic Neuropathy quality of life questionnaire score, nutritional status (as evaluated by modified body mass index), motor function (as measured by NIS-weakness and timed 10-m walk test), and autonomic symptoms (as measured by the Composite Autonomic Symptom Score-31 questionnaire). Exploratory objectives include assessment of cardiac function and pathologic evaluation to assess nerve fiber innervation and amyloid burden. Safety of patisiran was also assessed throughout the study. Overall patisiran reduced the mean max serum TTR reduction by 87.8% from baseline in the patisiran treated group over 18 months. The LS mean change in the mNIS+7 from baseline at 18 months was -33.99 (p = 9.26x10^-6); (Patisiran -6.03; placebo +27.96). The LS mean change in the Norfolk QOL-DN from baseline at 18 months was -21.1 (p = 1.10x10^-6); (Patisiran -6.7; placebo +14.4). All secondary endpoints (e.g., NIS-W, R-ODS, COMPASS-31, etc.) also achieved statistical significance at 18 months. The investigators also concluded that patisiran therapy was relatively safe and well tolerated with no increases in the frequency of events for patisiran compared to placebo group by system organ class. Overall, 13 deaths occurred in the APOLLO study, however, none of these were considered related to the study drugs and were consistent with natural history. The majority of infusion-related reactions were mild in severity, with no severe or life-threatening, or serious reactions. These reactions decreased over time and led to treatment discontinuation in only 1 patient. The investigators concluded that patisiran treatment resulted in significant improvement in polyneuropathy relative to placebo while significantly reducing disease symptoms and disability, improvement in quality of life, nutritional status, strength, and ambulation seen with patisiran relative to placebo.1,8

In a subpopulation analysis of the APOLLO trial, investigators evaluated the threatment association of patisiran with regional left ventricular (LV) myocardial strain in cardiac manifestation in hATTR.11,12 The prespecified cardiac subpopulation (126 of 225 [56%]) comprised of patients with a baseline LV wall thickness of 13 mm or more and no history of hypertensive or aortic valve disease. Of the 126 patients included in the prespecified cardiac subpopulation, 36 patients (28.6%) received placebo and 90 patients (71.4%) received patisiran. At baseline, LV global longitudinal strain (GLS) was impaired and regional longitudinal strains were lowest in the basal segments with apical sparing. There were no differences in regional longitudinal strains between the treatment groups at baseline. Patisiran improved the absolute GLS (least-squares mean [SE] difference, 1.4% [0.6%]; 95% CI, 0.3%-2.5%; P = .02) compared with placebo at 18 months, with the greatest differential increase observed in the basal region (overall least-squares mean [SE] difference, 2.1% [0.8%]; 95% CI, 0.6%-3.6%; P = .006) and no significant differences in the mid and apical regions among groups. Patisiran reduced mean left ventricular wall thickness (least-squares mean difference ± SEM: -0.9±0.4 mm, P=0.017), interventricular septal wall thickness, posterior wall thickness, and relative wall thickness at month 18 compared with placebo. Patisiran also led to increased end-diastolic volume (8.3±3.9 mL, P=0.036), decreased global longitudinal strain (1.4±0.6%, P=0.015), and increased cardiac output (0.38±0.19 L/min, P=0.044) compared with placebo at month 18. Patisiran lowered N-terminal prohormone of brain natriuretic peptide at 9 and 18 months (at 18 months, ratio of fold-change patisiran/placebo 0.45, P<0.001). A consistent effect on N-terminal prohormone of brain natriuretic peptide at 18 months was observed in the overall APOLLO patient population (n=225). Median follow-up duration was 18.7 months. The exposure-adjusted rates of cardiac hospitalizations and all-cause death were 18.7 and 10.1 per 100 patient-years in the placebo and patisiran groups, respectively (Andersen–Gill hazard ratio, 0.54; 95% CI, 0.28–1.01). The authors concluded that patisiran prevented the deterioration of LV GLS and decreased mean LV wall thickness over 18 months, suggesting that patisiran may halt or reverse the progression of the cardiac manifestations of hATTR amyloidosis.

U.S. FOOD AND DRUG ADMINISTRATION (FDA)

Onpatro™ (patisiran) contains a transthyretin-directed small interfering RNA and is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS)

Medicare does not have a National Coverage Determination (NCD) for ONPATTRO® (patisiran). Local Coverage Determinations (LCDs) do not exist at this time.

In general, Medicare covers outpatient (Part B) drugs that are furnished “incident to” a physician’s service provided that the drugs are not usually self-administered by the patients who take them. Refer to the Medicare Benefit Policy Manual, Chapter 15, 850 - Drugs and Biologicals. (Accessed April 11, 2019)

REFERENCES


POLICY HISTORY/REVISION INFORMATION

<table>
<thead>
<tr>
<th>Date</th>
<th>Action/Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>08/01/2019</td>
<td>Template Update</td>
</tr>
<tr>
<td></td>
<td>Reorganized policy template; relocated Background and FDA sections</td>
</tr>
<tr>
<td></td>
<td>Coverage Rationale</td>
</tr>
</tbody>
</table>
|            | Revised medical necessity criteria; replaced criterion requiring "patient is not receiving Onpattro in combination with tafamidis meglumine" with "patient is not receiving Onpattro in combination with Vyndaqel (tafamidis meglumine) or Vyndamax (tafamidis)"
|            | Supporting Information |
|            | Updated Clinical Evidence, CMS, and References sections to reflect the most current information |
|            | Archived previous policy version 2018D0072D |

INSTRUCTIONS FOR USE

This Medical Benefit Drug Policy provides assistance in interpreting UnitedHealthcare benefit plans. When deciding coverage, the member specific benefit plan document must be referenced as the terms of the member specific benefit plan may differ from the standard benefit plan. In the event of a conflict, the member specific benefit plan document governs. Before using this policy, please check the member specific benefit plan document and any applicable federal or state mandates. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Benefit Drug Policy is provided for informational purposes. It does not constitute medical advice.

This Medical Benefit Drug Policy may also be applied to Medicare Advantage plans in certain instances. In the absence of a Medicare National Coverage Determination (NCD), Local Coverage Determination (LCD), or other Medicare coverage guidance, CMS allows a Medicare Advantage Organization (MAO) to create its own coverage determinations, using objective evidence-based rationale relying on authoritative evidence (Medicare IOM Pub. No. 100-16, Ch. 4, §90.5).

UnitedHealthcare may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. UnitedHealthcare Medical Benefit Drug Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Onpattro™ (Patisiran)
UnitedHealthcare Commercial Medical Benefit Drug Policy

Proprietary Information of UnitedHealthcare. Copyright 2019 United HealthCare Services, Inc. Effective 08/01/2019